Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2005

View Archived Issues

Ondansetron reported to improve memory function in schizophrenia

Trabectedin shows antitumor activity in relapsed or refractory ovarian carcinoma

Corlux prevents olanzapine-induced weight gain in rats

Enrollment completed in phase III study of Thymitaq for HCC

A new immunostimulat from intestinal Eimeria

Early termination of phase III study of gefitinib for advanced lung cancer

Debiopharm and NanoCarrier form platinum compound research collaboration

Shire to acquire Transkaryotic Therapies

Trexima achieves endpoints in second phase III trial

Progression of pivotal study of MBP-8298 for secondary progressive MS

Evaluation of peptide deformylase inhibitor LBM-415's antimicrobial activity / News in Context

ST-294: Orally bioavailable small-molecule antiviral agent for New World Arenaviruses

Preclinical results from lead smallpox drug ST-246

BioCurex's RECAF blood test detects 92% of cervical cancers

Guilford restarts Aquavan program

SX-007 prolongs survival of mice with glioblastoma

FXa inhibitor reduces metastasis without anticoagulant-associated side effects

New patents cover treatments for cancer

Agreement on label wording for 5 mg dose of Crestor in Europe

MP-412: a promising compound for the treatment of EGFR/HER2-expressing tumors

Positive opinion handed down in Europe for new Temodal indication

Preclinical studies demonstrate that CYT-997 is a promising antitumor candidate

Preclinical antitumor activity of phase I PharmaMar compound

Eisai synthesizes novel antimitotic agent related to hemiasterlin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...